MannKind Corporation (MNKD) Reveals 2026 Growth Drivers

MannKind Corporation (NASDAQ:MNKD) is one of the Stocks to Buy Under $10 with High Potential. On January 8, MannKind Corporation (NASDAQ:MNKD) provided business updates and highlighted 2026 growth drivers.

Management noted that they closed fiscal 2025 on a high note with record fourth quarter revenue exceeding $100 million. Looking ahead, the company expects to achieve significant regulatory milestones. Management noted that the FDA is set to provide Afrezza label updates on January 23. The update is expected to simplify dosing for patients switching from injectable rapid-acting insulin, thereby potentially boosting adoption among adults with diabetes.

Moreover, a sBLA for Afrezza also has a PDUFA target of May 29, 2026. Management noted that an approval will result in the first needle-free insulin for pediatrics. Lastly, the FDA has also expected a sNDA for the FUROSCIX ReadyFlow Autoinjector, with a July 26, 2026, PDUFA date. MannKind Corporation (NASDAQ:MNKD) believes that if approved, this will allow the delivery of an 80 mg/ml IV-equivalent diuretic dose in under 10 seconds.

That said, Wall Street is bullish on the stock. Recently, on January 13, Gregory Renza from Truist Financial reiterated a Buy rating on the stock without disclosing any price targets. Earlier, on January 9, Brandon Folkes from H.C. Wainwright also reiterated a Buy rating on the stock with a price target of $11.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases. The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.